COMPANY

Elektrofi

Status: Acquired, now part of Halozyme · How status works

Our hyper concentration microparticle platform, Hypercon™, resolves the formulating and volume delivery limitations associated with intravenous biologic therapies by developing low-volume, stable, hyper concentrated biologic formulations for subcutaneous delivery. From company website Source · Oct 13, 2026

Keywords: formulations

Profile checked Oct 10, 2026

$112.2MRaised (2 yrs)

Timeline

Oct 31, 2024 Raise Private equity round — Series C: $112.25M (total, as published), announced Oct 31, 2024. Source: company's own press page. source ↗

Funding

Raised: $112.2M. Last 2 years.

Oct 31, 2024 Private equity round — Series C: $112.25M (total, as published), announced Oct 31, 2024. Source: company's own press page. source ↗